Clin2
NCT07641283Possibly a fitNot yet recruiting

Naltrexone to reduce self-injury behaviors

Nonsuicidal Self-InjurySelf-Injurious Behavior

Treatments studied

Part of Mental health clinical trials.

This study tests whether naltrexone, a medication that blocks opioid receptors in the brain, can reduce nonsuicidal self-injurious behavior (like cutting or burning). Researchers believe this medication may help decrease the urge to self-injure.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
150 people
Ages
16 years and older
Study type
Interventional

Who can take part

  • You are at least 16 years old
  • You engage in clinically significant self-injury (such as cutting, scratching, or burning yourself on purpose)
  • You are not currently having serious thoughts of suicide or at high suicide risk
  • You are not using opioids, opioid medications, or other opioid-blocking drugs
  • You have no serious liver or kidney problems
  • You speak and read Korean well enough to complete study assessments

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06622239Not yet recruiting· Phase 2
Naltrexone for reducing self-injury urges

This trial tests a medication called naltrexone to see if it can reduce the urge to hurt yourself. If you have a strong, repeated urge to self-injure, this treatment might help you feel more in control.

Seoul
NCT05028062Recruiting· Phase 4
Naltrexone injections for people who want to cut alcohol drinking

This Phase 4 study tests whether naltrexone injections can help people with alcohol use disorder (AUD) reduce or stop heavy drinking. You may get two injections over 8 weeks, and you can join if you meet specific drinking pattern and eligibility rules.

Philadelphia, Pennsylvania
NCT07433413Not yet recruiting· Phase 3
Naltrexone implant for alcohol use disorder

This trial tests a naltrexone implant designed to help people with moderate to severe alcohol use disorder cut down on drinking. The implant slowly releases medication for several months, so you don't have to remember to take a pill every day.

NCT07269873Recruiting· Phase 1
Testing a new implant for opioid use disorder

This study tests a new implant (BICX104) with or without bupropion to see how safe it is and how it works in the body, compared to an existing treatment (Vivitrol). If you are healthy and not using opioids, you may be eligible to help researchers understand if this implant could be a new option for treatment.

Miami, Florida
NCT05382091Not yet recruiting· Phase 2
Long-acting naltrexone implant to help prevent opioid relapse

This Phase 2 study tests whether a long-acting naltrexone implant can help people with opioid use disorder stay away from opioid relapse. You may get the implant after safely finishing opioid withdrawal and stopping other naltrexone dosing at the right time.

NCT06633900Recruiting· Phase 2/Phase 3
Testing naltrexone to prevent overdose in stimulant users

This trial tests whether naltrexone, a medication that blocks the effects of opioids, can help prevent overdose in people who use stimulants like cocaine or methamphetamine. It may be a good fit if you are at risk for HIV or living with HIV, and have a stimulant use disorder or use stimulants at least 10 days per month.

San Francisco, California

Hear when a new Nonsuicidal Self Injury trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.